APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/340,522	12/29/2011	Joseph J. Buggy	25922-819.301	7251
WILSON, SONSINI, GOODRICH & ROSATI 650 PAGE MILL ROAD PALO ALTO, CA 94304-1050			EXAMINER	
			RAMACHANDRAN, UMAMAHESWARI	
			ART UNIT	PAPER NUMBER
			1627	
			MAIL DATE	DELIVERY MODE
			03/13/2013	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

PTOL-90A (Rev. 04/07)



	RAMACHANDRAN			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply				
WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.	6(a) In no event, however, may a reply be timely filed ill apply and will expire SIX (6) MONTHS from the mailing date of this communication. cause the application to become ABANDONED (35 U.S.C. § 133).			
Status				
1) Responsive to communication(s) filed on 04 Fe	ebruary 2013.			
2a) This action is <b>FINAL</b> . 2b) ☑ This	action is non-final.			
3) An election was made by the applicant in response	onse to a restriction requirement set forth during the interview on			
; the restriction requirement and election	have been incorporated into this action.			
4) Since this application is in condition for allowar	nce except for formal matters, prosecution as to the merits is			
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 453 O.G. 213.			
Disposition of Claims				
5) Claim(s) 131,132 and 134-149 is/are pending i	n the application.			
5a) Of the above claim(s) is/are withdray	• •			
6) Claim(s) is/are allowed.				
7) Claim(s) <u>131,132 and 134-149</u> is/are rejected.				
8) Claim(s) is/are objected to.				
9) Claim(s) are subject to restriction and/or	election requirement.			
* If any claims have been determined <u>allowable</u> , you may program at a participating intellectual property office for t <a href="http://www.uspto.gov/patents/init_events/pph/index.jsp">http://www.uspto.gov/patents/init_events/pph/index.jsp</a> or	be eligible to benefit from the <b>Patent Prosecution Highway</b> he corresponding application. For more information, please see r send an inquiry to <a href="mailto:PPHfeedback@uspto.gov">PPHfeedback@uspto.gov</a> .			
Application Papers				
10) The specification is objected to by the Examine	r.			
11) The drawing(s) filed on is/are: a) acce				
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correct	ion is required if the drawing(s) is objected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119				
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:	, , , , , , , , , , , , , , , , , , , ,			
1. Certified copies of the priority documents	s have been received.			
2. Certified copies of the priority documents				
	ity documents have been received in this National Stage			
application from the International Bureau				
* See the attached detailed Office action for a list				
Attachment(s)				
1) Notice of References Cited (PTO-892)	3) Interview Summary (PTO-413) Paper No(s)/Mail Date			
2) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 1/23/2013, 2/22/2013.	4) Other:			





### **DETAILED ACTION**

The office acknowledges Applicants' response to the Restriction Election dated 1/3/2013. Applicants' have elected Group II with traverse. Applicants' argue that a relapsed or refractory non-Hodgkin's lymphoma is a species of relapsed or refractory hematological malignancy, the claims Group III overlap and are encompassed by the genus relapsed or refractory hematological malignancy. Also, Applicants have amended claim 132 to depend from claim 131. Accordingly, claims 131,132, and 134-149 as presented herein read on elected Group II. Applicants' arguments and amendment of claims have been considered and found to be persuasive. Applicants have cancelled claims 1-130, 133. Claims 131, 132, 134-149 are directed to a method of relapsed or refractory hematological malignancy in an individual comprising administering to the individual an inhibitor of Bruton's tyrosine kinase (Btk). Hence Group II and Group III claims (131, 132, 134-149) will be examined. Applicants have elected the species of lymphoma – mantle cell lymphoma (MCL), species of second cancer agent - rituximab (174722-31-7) and the following species for Btk inhibitor.

RN 936563-96-1 HCAPLUS
CN 2-Propen-1-one, 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]- (CA INDEX NAME)

(stereoisomer – ibrutinib – PCI-32765 (936563-96-1), (specification p 82, [00262, compound 1], in US publication, p 34, compound 1). The claims will be examined to the extent they read on the elected species.

The restriction requirement election is made Final.

Note: The claim set dated 3/26/2012 that was examined for Restriction Election Requirement had claim 150. However the claim set dated 2/4/2013 (examined for this office action) do not have claim 150 and there is no cancelled claim 150.

The claims corresponding to the elected subject matter are 131, 132, 134-149 are herein acted on the merits.

## Application Priority

This application filed 12/29/2011 is a continuation of 13153317, filed 06/03/2011, Claims Priority from Provisional Application 61351130, filed 06/03/2010, Claims Priority from Provisional Application 61351655, filed 06/04/2010, Claims Priority from Provisional Application 61351793, filed 06/04/2010, Claims Priority from Provisional Application 61351762, filed 06/04/2010, Claims Priority from Provisional Application 61419764, filed 12/03/2010, Claims Priority from Provisional Application 61472138, filed 04/05/2011.

### Information Disclosure Statement

The information disclosure statements (IDS) filed on 1/23/2013, 2/22/2013 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the IDS is being considered by the Examiner. The foreign references and non-patent literature



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

## **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

